EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 780 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR COVID-19 in people with cancer – what we know so far December 4, 2020 Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... October 24, 2025 No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... April 14, 2023 FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... March 23, 2026 Load more HOT NEWS Your Microbiome and Cancer: What to Know Immunotherapy for Breast Cancer Treatment: Is It an Option? OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens...
